Zhiyuan Tan
Promovendus
- Naam
- Mr. Z. Tan MSc
- ORCID iD
- 0000-0003-2681-6932
For more information look at the English website
Promovendus
Contact
- Tan Z. (31 maart 2026), From labelled to the optimal clinical dose: model-informed dose optimization in medical oncology practice (Dissertatie. Leiden Academic Centre for Drug Research (LACDR), Faculty of Science, Leiden University). Promotor(en) en copromotor(en): Knibbe C.A.J., Moes D.J.A.R. & Völler S.
- Tan Z., Völler S., Sancho‐Araiz A., Knibbe C.A.J. & Moes D.J.A.R. (2025), A systematic evaluation of the dosing regimens for approved targeted therapies and immune checkpoint inhibitors in metastatic renal cell carcinoma from a project OPTIMUS perspective, The Journal of Clinical Pharmacology 65(10): 1187-1207.
- Tan Z., Völler S., Yin A., Rieborn A., Gelderblom H., Hulle T. van der, Knibbe C.A.J. & Moes D.J.A.R. (2025), Model-informed dose optimization of pazopanib in real-world patients with cancer, Clinical Pharmacokinetics 64(5): 715-728.
- Tan Z., Völler S., Yin A., Rieborn A., Gelderblom A.J., Hulle T. van der, Knibbe C.A.J. & Moes D.J.A.R. (2024), Population pharmacokinetics of cabozantinib in metastatic renal cell carcinoma patients: towards drug expenses saving regimens, Clinical Pharmacokinetics 63(6): 857-869.